Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), very low-density...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rhogerry Deshycka, Valentino Sudaryo, Nai-Jia Huang, Yushu Xie, Liyan Y. Smeding, Moon Kyung Choi, Hidde L. Ploegh, Harvey F. Lodish, Novalia Pishesha
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/6e2cb9ebe8ff46288add6d9019ba5414
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!